NCT03605381: MORe PREcISE

MORbidity PRevalence Estimate In StrokE

Status unknown Last updated 5 July 2019

What this trial tests

trial in Stroke in 500 participants. Status unknown.

Timeline

30 September 2018

Primary endpoint
31 August 2019

30 September 2019

Quick facts

Lead sponsor	Aneurin Bevan University Health Board
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	500
Start date	30 September 2018
Primary completion	31 August 2019
Estimated completion	30 September 2019
Sites	3 locations across United Kingdom

Conditions studied

• Stroke — all drugs for Stroke →
• CVA (Cerebrovascular Accident) — all drugs for CVA (Cerebrovascular Accident) →
• CVA; Sequelae — all drugs for CVA; Sequelae →
• Stroke, Ischemic — all drugs for Stroke, Ischemic →

Sponsor

Aneurin Bevan University Health Board

Who can join

18 and older, any sex, with Stroke or CVA (Cerebrovascular Accident). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Information regarding the likely progress of post-stroke symptoms is vitally important to stroke survivors to allow them to plan for the future and to adjust to life after stroke. Moreover, the prevalence of morbidity secondary to stroke is of central importance to Health Professionals to understand the prognosis of the disease in the patients under their care. Additionally, it will also allow commissioners of care, planners and third sector organisations to adapt to and answer the needs of a post-stroke population.

Currently, the data collected by national audit programmes are concentrated on what can be termed 'process or process of care' data. The utility of these data are in the ability to audit the care received by stroke survivors on stroke units against evidenced standards for care, thus ensuring evidence based practice. Nevertheless, process of care is only one form of measuring stroke unit care and the audit programmes collect some limited functional status data, data relating to risk-factor co-morbidities and treatment received data. Therefore, the scope of this study is to build on the minimum data set currently collected and to collect post-stroke data in domains not currently collected.

The International Consortium for Health Outcomes Measurement (ICHOM) takes important steps to collect data outside of process of care data such as a Patient Reported outcome data in their minimum outcome data set for stroke \[currently under review\].. Nevertheless, the ICHOM doesn't currently advocate the specific collection of data relating to cognitive impairment or emotional problems secondary to stroke. It is in these important aspects that this study will augment the data set currently advocated by ICHOM to collect data in the areas of cognitive impairment and emotional problems secondary to stroke.

Therefore, the aim of this study is to quantify the prevalence of morbidity at six months post-stroke.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Morbidity Prevalence Estimate at 6 Months Following a Stroke: Protocol for a Cohort Study.
   Smith A, Bains N, Copeland L, Pennington A, et al · · 2020 · cited 2× · PMID 32512539 · DOI 10.2196/15851
2. E-Poster Viewing – Miscellaneous
   · 2019